News | Atrial Fibrillation | May 14, 2019| Dave Fornell, Editor

Rotor Ablation Fails to Beat Conventional Therapy in Persistent AFib

REAFFIRM Trial showed no increased benefit in treating drug refractory symptomatic persistent atrial fibrillation

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

The Abbott Topera FIRM Map basket catheter for electromapping the heart to perform ablation procedures.

The Abbott Topera FIRM Map basket catheter for electromapping the heart to perform ablation procedures.

May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein isolation (PVI) to FIRM-guided rotor ablation followed by PVI in persistent atrial fibrillation (AF) patients failed to provide evidence for Abbott FIRM plus PVI was superiority at 3-12 months. Results from the study were presented during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Catheter ablation is the cornerstone of therapy for drug refractory symptomatic persistent atrial fibrillation (PersAF). The exact pathophysiology of how pulmonary vein (PV) triggers initiate and/or maintain episodes of AF has been elusive. Previous work has shown higher acute and long-term efficacy with the addition of Focal Impulse and Rotor Modulated (FIRM)-guided ablation in AF patients.

The REAFFIRM Trial included 375 patients enrolled and randomized at 18 centers. The intent to treat (ITT) population consisted of 350 patients (25 patients with no catheter inserted were excluded), 171 in the FIRM arm and 179 in the conventional arm. Patients were followed for 12 months. Primary effectiveness was defined using dual endpoints: Single procedure freedom from AF/AT recurrence at 3 months or single procedure freedom from AF/AT recurrence from 3-12 months, after the initial ablation procedure.

Additional ablation beyond PVI was at physician discretion, not controlled for and represented nearly half of patients in the study, said presenter Prof. Johannes Brachmann, director for cardiology and angiology, Regiomed Kliniken, Coburg, Germany. He said effectiveness in both arms was higher than historically reported success rates, but this improvement may be related to higher operator experience, new technologies and different patient populations. Safety and efficacy of catheter ablation in the study proved the excellent performance of catheter ablation in this patient population.

A total of 324 patients (165 FIRM, 159 conventional) completed the 12-month follow-up. All baseline parameters were equally distributed except for a small, but significantly (P <0.01) larger LA diameter in the FIRM arm. Ablation was limited to PVI only in 51% (91/177) of conventional patients and 59% (96/164) of FIRM-guided +PVI patients. Primary effectiveness (ITT population) showed no significant difference between arms. Single procedure freedom of AF/AT recurrence from 3-12 months was 69.3% (115/166) in the FIRM group and 67.5% (110/163) in the conventional group (P = 0.96). There was no significant difference at either the seven-day or 12-month safety endpoints. Ablation procedure time was comparable and the percentage of repeat procedures did not differ significantly. 

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

 

Related Content:

VIDEO: Current State of Atrial Fibrillation Ablation Technologies — Interview with Hugh Calkins, M.D.,

New Technologies to Improve Atrial Fibrillation Ablation

Landmark CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy

VIDEO: Cryoballoon Ablation Best Practice Guidelines — Wilber Su, M.D.

Meeting the Treatment Demands of a Growing AFib Epidemic
 

 

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init